Vulcan Two Group plc (LSE:VUL) has published its first results since buying three ePharmacy businesses in March, reporting £10.0m of Revenue and a £4.1m pre-tax loss for the period from Acquisition to 30 June 2026. The AIM-quoted group is changing its name to Molecule Group plc.
What was announced
Vulcan Two Group plc (LSE:VUL) released interim results for the six months to 30 June 2026 alongside confirmation of a change of name. The company will become Molecule Group plc, trading under the ticker MOL, with the change expected "in the coming days". A new investor website, investors.molecule.co.uk, accompanies the Molecule consumer Brand and the molecule.co.uk site, which have already launched.
The results are the group's first since it completed the acquisition of CloudRx, a business-to-business prescription fulfilment operator, Webmed, a business-to-consumer digital pharmacy, and Hyperdrug, a veterinary pharmacy, on 19 March 2026. The company gives a maximum consideration of £41.7m. The detailed breakdown shows £36.36m in cash, £2.36m non-cash, £1.0m of rollover Loan notes and up to £0.53m of deferred consideration. The deals were funded by a £40.0m share placing in March.
The numbers
Reported figures cover only the period from 19 March to 30 June 2026, roughly three and a half months:
- Revenue of £10.0m
- Gross profit of £2.2m, a 22% margin
- Adjusted EBITDA loss of £0.6m
- Loss before tax of £4.1m, including £2.8m of one-off acquisition costs covering legal, accounting and advisory fees and stamp duty
Reported revenue came 29% from Weight Loss, 49% from General Healthcare and 22% from Veterinary.
The company also gives pro-forma figures as if the businesses had been owned for the full six months. On that basis, revenue was £19.9m, Gross Profit £4.1m (21% margin), adjusted EBITDA a positive £0.5m, and the loss before tax £1.9m. The pro-forma mix was Weight Loss 33%, General Healthcare 44% and Veterinary 23%.
At 30 June the group held £5.7m in cash and had net Assets of £44.3m. Intangible assets were £44.2m, including £27.2m of Goodwill and £12.9m of customer relationships. The company says 85% of revenue comes from customers who pay at the point of order. No Dividend is mentioned.
Integration and management
The group is building a single platform. Webmed's fulfilment has moved to CloudRx, and the company has cut back lower-margin clinic relationships that carried higher Credit risk. A 22,000 sq ft distribution centre in Leeds is expected to be operational in early December 2026, and staff are relocating to the Leeds operational centre from the fourth quarter. The rollout of an enterprise resource planning (ERP) system is on track to finish in December. A dedicated B2B sales team has been added.
Keith Butcher has been appointed chief financial officer and Declan Lismore chief pharmacy officer. Michael Kraftman remains chief executive and Brendan O'Brien chief operating officer.
What to watch next
The company's outlook states: "2026 remains a year of Investment and integration as the Group builds its single brand scalable platform, with the distribution centre completion and ERP system implementation on track for Q4." Kraftman said operating costs are higher this year because legacy and new systems are running side by side, and that "those duplicated costs fall away in 2027". This is the company's own expectation.
The board says it "remains confident in the Company's growth strategy" and believes the group "is well positioned to capitalise on the opportunities in the UK ePharmacy market". No numerical guidance is given.
The next milestones are the formal name change and new ticker, the Leeds site opening, and completion of the ERP rollout. Full-year results will include the whole second half under the group's ownership, following the March completion.


_11_18_2026_11_51_48_599283.jpg)



Please wait processing your request...